Details for New Drug Application (NDA): 020469
✉ Email this page to a colleague
NDA 020469 describes VANCENASE AQ, which is a drug marketed by Schering and is included in two NDAs. Additional details are available on the VANCENASE AQ profile page.
The generic ingredient in VANCENASE AQ is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
The generic ingredient in VANCENASE AQ is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
Summary for 020469
| Tradename: | VANCENASE AQ |
| Applicant: | Schering |
| Ingredient: | beclomethasone dipropionate monohydrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | EQ 0.084MG DIPROP/SPRAY | ||||
| Approval Date: | Jun 26, 1996 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
